Ann: Immutep Global Webcast Slides to Discuss Clinical Results, page-20

Received further clarification on Potential new studies financed :



Use of FundsThe Company will use the proceeds received from the Placement to fund an expanded clinical program including the following:New Phase III Registration Trial–metastatic breast cancer (based on AIPAC)New Phase IITrial–triple combination therapy with efti + anti-PD-1 therapy + chemotherapy (expected indication: NSCLC)Other Trials – two new investigator-initiated trials (IITs) with up to 40 patients eachManufacturing & validation–commence process characterisation and process validation for efti commercial manufacturing (2,000 litre scale)Regulatory–ongoing interactions with the FDA and EMAAutoimmune Program–IND package for IMP761Strengthen–the team and research projects